



WORKING WITH COMPANIES POLICY

September 2022

admin@gistcancer.org.uk

GIST Cancer UK

www.gistcancer.org.uk

Registered Charity Number: 1129219

GCUK Policy on Working with Companies

Policy

Pharmaceutical and biotechnology companies play a central role in developing and delivering new diagnostic tests, therapies and treatments to patients with GIST cancer. By working with these industries, we have an opportunity to support and accelerate the development of innovative new treatments and tests that meet the needs and preferences of GIST cancer patients. Collaboration can take many forms, ranging from donations to working together and sharing advice and expertise.

All of our work with such companies complies with this policy, and in all dealings with companies we will continue to uphold our commitment to transparency, impartiality and independence.

How we work with companies

GCUK's policy for working with the medicine, device, diagnostics, allied and private healthcare industries is based upon the following core principles:

1. **Independence:** GCUK will always maintain its independence. We will remain free to comment, both positively and negatively in relation to the company, in the interest of people affected by GIST cancer.
2. **Integrity:** GCUK will always act with honesty and integrity. We expect adherence to similarly high standards by all companies with whom we develop relationships.
3. **Transparency:** GCUK will be open about any collaboration and be able to account publicly for the associated activities and any exchanges of funding with, and from, pharmaceutical companies.

Taking into consideration these core principles, we only work with companies when:

- The company complies with the standards set out in the Association of British Pharmaceutical Industries (ABPI) Code of Practice, and in particular Clause 27 which relates to working with patient groups.
- We have carried out, and are satisfied with due diligence checks.
- The terms of the collaboration or funding are clearly set out in a written agreement, signed by both parties.
- Any intellectual property generated remains with the charity.
- The collaboration will not result in one company gaining a competitive advantage over another.
- Publications or products generated as a result of industry sponsorship carry our logo and the source of funding is transparent.
- The relationship/activity is not subject to any conditions that are unacceptable to, or prevent us from acting in the best interests of, people with or affected by GIST cancer.
- The company does not seek to influence the charities strategy, projects or activities, either explicitly or implicitly.
- No person acting on behalf of GIST Cancer Research is permitted to accept a personal payment from any company. The charity will accept honoraria, fees and reimbursement of expenses provided the CEO is satisfied that participation is consistent with the terms of this policy.

References

This policy considers the Association of Medical Research Charities' (AMRC) publication, "An Essential Partnership Principles & Guidelines for Working with Industry" 2014 and complies with the Charity Commission guidelines 'Fundraising through Partnerships with Companies'.